Thymosin Beta-4

Overview

Thymosin Beta-4 (Tβ4) is a 43-amino-acid endogenous protein found in virtually all mammalian cells. It is one of the principal actin-binding proteins in the cell. Actin is the building material of the cytoskeleton, the internal framework that gives a cell its shape and lets cells move. By binding free actin building blocks, Tβ4 regulates how much of that material is available, and thereby influences cell movement, cell division, and the way tissue responds to injury.

Tβ4 is studied in the context of tissue repair, wound healing, inflammation, and the formation of new blood vessels (angiogenesis). Because of its central role in actin regulation, it touches on many different repair processes at once. That broad reach is what makes it scientifically interesting, and at the same time hard to study, because a single molecule intervenes in so many processes.

One important distinction up front. Tβ4 is the full, endogenous protein. In the research-peptide market the name "TB-500" also circulates; that is a synthetic fragment of only seven amino acids, derived from a small active region of Tβ4. The two are routinely conflated, but they are chemically and structurally different, and the clinical research described below has been done almost exclusively with the full-length Tβ4 protein, not with the fragment. (The fragment has its own profile in this database.)

Indexed in over 1,000 PubMed publications, as of May 2026. This profile summarises the current state of research. It does not constitute efficacy claims or product recommendations.

Mechanism of action

Thymosin Beta-4 binds free actin monomers (G-actin) and holds them in reserve, regulating the balance between free G-actin and the polymerised, filamentous F-actin form. That balance governs how quickly a cell can assemble and disassemble its cytoskeleton, the basis of cell motility. Tβ4 itself is largely intrinsically disordered in solution; it folds into a stable structure only when bound to actin.

Actin binding and cytoskeletal regulation

• Binds free G-actin and holds it in reserve, regulating the G-actin / F-actin equilibrium
• That equilibrium governs how quickly a cell can assemble and disassemble its cytoskeleton, the basis of cell motility
• Largely intrinsically disordered in solution; folds into a stable structure only upon actin binding

Cell migration and tissue repair

• By steering actin dynamics, promotes cell migration toward sites of injury, a first step in wound closure
• Stimulates new blood vessel formation (angiogenesis) in preclinical (cell- and animal-based) models
• Supports survival of cells around the wound in preclinical settings

Inflammation dampening and Ac-SDKP

• Dampens inflammatory signalling in injury models, including modulation of chemokines that recruit inflammatory cells
• Degradation of Tβ4 can yield the smaller fragment Ac-SDKP, linked in research to anti-fibrotic effects (reduction of excessive scar tissue)
• Ac-SDKP is a different portion of the protein than the region on which TB-500 is based

Research findings

• Ophthalmology: most clinical development concerns Tβ4 eye drops (investigational name RGN-259); multiple large placebo-controlled phase 3 trials in dry eye syndrome have been completed
• Neurotrophic keratopathy: a phase 3 trial of RGN-259 is ongoing; no ophthalmic indication has reached market authorisation
• Skin wound healing: phase 2 trials in difficult-to-heal wounds (venous leg ulcers, pressure ulcers, each around 72 participants); completed but not advanced to phase 3
• Cardiac repair: mixed signals; a US trial of injectable Tβ4 was withdrawn before start, while a Chinese development line with recombinant human Tβ4 has completed phase 2 with follow-up in preparation
• Preclinical: broad and consistent evidence for repair of skin, cornea, cardiac, and nerve tissue in animal and cell models; signal does not automatically translate into proven human efficacy

Ophthalmology: most clinically advanced

• Multiple completed placebo-controlled phase 3 trials of Tβ4 eye drops (RGN-259) in dry eye syndrome, including studies with around 600 and 700 participants
• Phase 3 trial in neurotrophic keratopathy currently ongoing
• No ophthalmic indication has reached market authorisation to date

Skin and cardiac repair

• Completed phase 2 trials in venous leg ulcers and pressure ulcers (≈72 participants each), not advanced to phase 3
• US cardiac trial with injectable Tβ4 withdrawn before start
• Active Chinese development line with recombinant human Tβ4 in cardiac repair, with completed phase 2 and follow-up in preparation

Preclinical signal

• Broad evidence across skin, cornea, cardiac, and nerve tissue in animal and cell models
• Consistent signal on cell migration, angiogenesis, and anti-inflammatory action
• Preclinical consistency does not automatically translate into demonstrated human efficacy

Research context

Tβ4 is one of the better-studied peptides in tissue-repair research, with a large preclinical literature and a clinical dossier that reaches further than that of most research peptides. It is clinically most advanced in ophthalmology.

There is a clear limit. Despite two decades of research, no indication has reached market authorisation; the skin-wound trials stopped at phase 2; and the first US cardiac trial was withdrawn. Promising biology and proven clinical effect are not the same thing, and that distinction matters here.

The relationship to TB-500 deserves emphasis, because public sources tend to simplify it. TB-500 is derived from the active region of Tβ4, but the two are not interchangeable. Findings from Tβ4 research should not be transferred without qualification to the fragment, and vice versa. Virtually all clinical data above concern the full-length protein.

Open questions

Tβ4 has strong preclinical support and an unusually broad clinical dossier for a research peptide, but no indication has yet reached market authorisation. Specific application claims should be evaluated against the available evidence.

• Despite extensive research, no indication has reached market authorisation; ongoing phase 3 ophthalmic trials must show whether that changes
• Clinical evidence outside ophthalmology is thinner; controlled trials in skin and cardiac repair would broaden the picture
• Efficacy of the full-length protein versus derived fragments has not been systematically compared head-to-head
• Long-term safety profile of exogenous administration is not well characterised
• Dose-response relationships differ by tissue type and have not been systematically established

Research outlook

Readout of the ongoing phase 3 ophthalmic trials and of the Chinese cardiac development line

Controlled human studies in tissue repair beyond ophthalmology

Systematic comparison of full-length Tβ4 and derived fragments under standardised conditions

Long-term safety characterisation of exogenous administration

Scientific interest

One of the principal actin-binding proteins in the cell, fundamental to cell motility and cytoskeletal biology

Clinically most advanced in ophthalmology (corneal wound healing, dry eye)

Broad preclinical signal across skin, cardiac, and ocular repair models

Scientific reference point for understanding TB-500 and other fragment research

Specifications

References

1. Thymosin beta 4 interactions · Bubb MR · Vitamins and Hormones · 2003
2. β-Thymosins · Hannappel E · Annals of the New York Academy of Sciences · 2007
3. Animal studies with thymosin beta4, a multifunctional tissue repair and regeneration peptide · Philp D, Kleinman HK · Annals of the New York Academy of Sciences · 2010
4. Thymosin-β4 prevents cardiac rupture and improves cardiac function in mice with myocardial infarction · Peng H, et al. · Am J Physiol Heart Circ Physiol · 2014
5. Thymosin β4 coated nanofiber scaffolds for the repair of damaged cardiac tissue · Kumar A, Patel A, Duvalsaint L et al. · Journal of Nanobiotechnology · 2014
6. Advances in the basic and clinical applications of thymosin β4 · Goldstein AL, Kleinman HK · Expert Opinion on Biological Therapy · 2015
7. ARISE-3: A Phase 3 Study of RGN-259 Ophthalmic Solution for Dry Eye Syndrome (NCT03937882) · ReGenTree LLC · ClinicalTrials.gov · 2022
8. SEER-2: A Phase 3 Study of RGN-259 for Neurotrophic Keratopathy (NCT05555589) · ReGenTree LLC · ClinicalTrials.gov · 2023

Availability

Not in catalogue · Profile complete · verification and sourcing not yet finished